Impact of COVID-19: Management of Early-Stage Breast Cancer

Video

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Anthony Lucci, MD, provides closing thoughts on the management of early-stage breast cancer moving forward given what we have learned from the COVID-19 pandemic.

      Recent Videos
      Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
      Pivotal Presentations That May Shape the Breast Cancer Standard of Care
      Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
      Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
      Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
      Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
      Navigating Treatment/Testing Decisions in Metastatic HR+/HER2– Breast Cancer
      Navigating Treatment/Testing Decisions in Metastatic HR+/HER2– Breast Cancer
      Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
      Breast Cancer Disparities May Fuel Guideline-Concordant Care Improvements
      Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
      Medical Education May Improve Care for Breast Cancer Minority Populations
      The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
      Low Breast Cancer Guideline-Concordant Care Use Indicates Racial Disparities
      Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
      Addressing Racial Disparities, Social Barriers to Breast Cancer Care
      Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies
      Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies
      Chemotherapy Results in Greater Pain/Fatigue Vs Endocrine Therapy in Breast Cancer
      Chemotherapy Results in Greater Pain/Fatigue Vs Endocrine Therapy in Breast Cancer
      Related Content
      42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

      42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

      Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
      May 29th 2025
      Article
      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

      Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
      April 21st 2025
      Podcast

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

      45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

      Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
      May 27th 2025
      Article
      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

      Paolo Tarantino, MD;Matteo Lambertini, MD
      January 13th 2025
      Podcast

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

      46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

      Heather McArthur, MD, MPH;Peter A. Fasching;Rebecca Dent, MD;Javier Cortés, MD;Lajos Pusztai, MD, DPhil;Sherko Kuemmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Seock-Ah Im;Michael Untch, MD, PhD;Marie-Ange Mouret-Reynier;Theodoros Foukakis;Marta Ferreira;Fatima Cardoso;Yu Ding;Cecilia Pinheiro;Jaime Mejia;Joyce A. O’Shaughnessy;Peter Schmid, MD
      May 26th 2025
      Article
      48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

      48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

      Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
      May 25th 2025
      Article